http://www.lockslaw.com/blog Pennsylvania, New York, and New Jersey Personal Injury Lawyers — Locks Law Firm Fri, 27 Aug 2010 14:26:27 +0000 http://backend.userland.com/rss092 en The Avandia news continues. Just last month, there was a meeting of a joint advisory committee reporting to the Food and Drug Administration (FDA) concerning the potential health risks of the diabetes drug Avandia. This was the second meeting of this committee. It originally met in July ... http://www.lockslaw.com/blog/2010/08/significant-risk-of-heart-attack-with-avandia-is-the-fda-protecting-you/ The hits just keep coming for drug giant J&J who recently issued recalls for some its most popular and profitable products like Children’s Tylenol, and just last week, its Acuvue contact lenses had to be pulled from the Asian and European markets. Yesterday, J&J’s DePuy Orthopedic division recalled the ... http://www.lockslaw.com/blog/2010/08/johnson-johnson%e2%80%99s-depuy-orthopedic-unit-pulls-hip-implants-from-market/ Further to my June 24 blog and as reported in the The Boston Globe, Harvard Medical School has joined the ranks of medical educational facilities that have enacted new, tough conflict-of –interest rules affecting the payment of educators and others by Big Pharma and Medical Device manufacturers. Under its new ... http://www.lockslaw.com/blog/2010/07/harvard-medical-school-says-no-to-big-pharma-and-device-manufacturer-money/ The good news keeps coming for Glaxo, the pharma giant that makes the diabetes drug Avandia. Yesterday the FDA ordered Glaxo to stop patient enrollment in a study that compared Avandia to a competing drug Actos, and to warn all patients already enrolled that Avandia may increase the risk ... http://www.lockslaw.com/blog/2010/07/fda-tells-glaxo-to-halt-enrollment-in-avandia-drug-trial/ As a follow-up to my blog post of July 16, 1010, the Wall Street Journal today reports that an FDA panelist who voted to leave Glaxo’s diabetes drug Avandia on the US market with no additional restrictions received---wait for it folks---money from the drug maker for being a ... http://www.lockslaw.com/blog/2010/07/fda-panelist-who-backed-avandia-in-hearings-is-paid-by-glaxo/ After 2 days of intensive hearings, the FDA Advisory Panel charged with oversight of the Glaxo-SmithKline diabetes drug Avandia (Rosiglitazone) recommend to FDA that the drug be either withdrawn or otherwise its use should be severely restricted. The ruling came as a result of analyses done of GSK studies ... http://www.lockslaw.com/blog/2010/07/fda-advisory-panel-recommends-avandia-be-withdrawn-or-severely-restricted-in-us/ Lawyers who bring claims for persons hurt by defective medical devices and drugs have long known that both industries provide significant funds---to the tune of 1.2 billion dollars---to finance continuing legal education for doctors. We also know that pharmaceutical and medical device companies sponsor “educational programs” for doctors ... http://www.lockslaw.com/blog/2010/06/doctors-debate-role-of-industry-money-in-funding-physician-education/ The Philadelphia Inquirer recently interviewed partner, Jim Pettit, for a breaking news story arising from mercury contamination at a daycare center in Franklin Township, Gloucester County, New Jersey. Mr. Pettit is the court-appointed Lead Counsel in several class actions concerning Kiddie Kollege Daycare. In 2006 the state closed the ... http://www.lockslaw.com/blog/2010/05/2301/ Partner, Jim Pettit, was asked to join a speaker panel on the topic of Courtroom Technology. The seminar on April 27 was sponsored by the Camden County Bar Association. Mr. Pettit's topic was Ten Technology Questions to Resolve Prior to Trial. http://www.lockslaw.com/blog/2010/04/jim-pettit-and-courtroom-technology/ On April 5, 2010, NHTSA announced that it will seek the maximum possible penalty from Toyota – over $16 million. The government accused Toyota of a cover up. Under federal law, Toyota had five days to report problems with “sticking” gas pedals but instead waited months to take ... http://www.lockslaw.com/blog/2010/04/toyota-acceleration-cases/